Phase I trial of ICT-107 in glioblastoma

Trial Profile

Phase I trial of ICT-107 in glioblastoma

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs ICT 107 (Primary) ; Antineoplastics
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Nov 2016 Results published in an ImmunoCellular Therapeutics Media Release
    • 21 Nov 2016 According to an ImmunoCellular Therapeutics media release, updated long-term survival data from this trial at the 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
    • 22 Aug 2016 Updated long-term survuval data from this trial will be presented at the Society for NeuroOncology Annual Scintific Meeting 2016, according to an ImmunoCellular Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top